Immunic Inc (NASDAQ:IMUX)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.86. At the close of trading, the stock’s price was $1.28, to imply an increase of 4.92% or $0.06 in intraday trading. The IMUX share’s 52-week high remains $2.11, putting it -64.84% down since that peak but still an impressive 24.22% since price per share fell to its 52-week low of $0.97. The company has a valuation of $115.30M, with an average of 0.9 million shares in intraday trading volume over the past 10 days and average of 876.54K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Immunic Inc (IMUX), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give IMUX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.

Immunic Inc (NASDAQ:IMUX) trade information

After registering a 4.92% upside in the last session, Immunic Inc (IMUX) has traded red over the past five days. The 5-day price performance for the stock is 3.23%, and 8.47% over 30 days. With these gigs, the year-to-date price performance is -14.67%. Short interest in Immunic Inc (NASDAQ:IMUX) saw shorts transact 3.8 million shares and set a 2.96 days time to cover.

The extremes give us $5 and $5 for target low and target high price respectively. As such, IMUX has been trading -290.62% off suggested target high and -290.62% from its likely low.

Immunic Inc (IMUX) estimates and forecasts

Looking at statistics comparing Immunic Inc share performance against respective industry, we note that the company has outperformed competitors. Immunic Inc (IMUX) shares are 4.07% up over the last 6 months, with its year-to-date growth rate higher than industry average at 53.08% against 17.50%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 31.12% for the past 5-year period. While 2024 is set for a 54.30% return in earnings, projections for the next 5 years are at 15.50% annually.

IMUX Dividends

Immunic Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Immunic Inc (NASDAQ:IMUX)’s Major holders

Immunic Inc insiders hold 3.44% of total outstanding shares, with institutional holders owning 64.85% of the shares at 67.16% float percentage. In total, 64.85% institutions holds shares in the company, led by BVF INC/IL. As of 2024-06-30, the company held over 8.9 million shares (or 9.15% of shares), all amounting to roughly $9.88 million.

The next major institution holding the largest number of shares is AVIDITY PARTNERS MANAGEMENT LP with 8.9 million shares, or about 9.15% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9.88 million.

We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Immunic Inc (IMUX) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 2.63 shares. This is just over 2.92% of the total shares, with a market valuation of $3.37 million. Data from the same date shows that the other fund manager holds a little less at 1.87, or 2.08% of the shares, all valued at about 2.39 million.